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Abstract: With the widespread use of O-alkoxyresorufin dealkylation assays since the 
1990s, thousands of inhibitors of cytochrome P450 family 1 enzymes (P450s 1A1, 1A2, 
and 1B1) have been identified and studied. Generally, planar polycyclic molecules such as 
polycyclic aromatic hydrocarbons, stilbenoids, and flavonoids are considered to potentially 
be effective inhibitors of these enzymes, however, the details of the structure-activity 
relationships and selectivity of these inhibitors are still ambiguous. In this review, we 
thoroughly discuss the selectivity of many representative P450 family 1 inhibitors reported 
in the past 20 years through a meta-analysis. 
Keywords: cytochrome P450; enzyme inhibitor; stilbenoids; flavonoids; structure activity 
relationships; mechanism-based inhibitor 
 
1. Introduction 
Cytochrome P450 enzymes are a large ubiquitous superfamily of enzymes, playing a significant 
physiological role in the detoxification of xenobiotics, and the biosynthesis of many endogenous 
compounds. P450 families 1, 2, and 3 contribute most extensively to the biotransformation of 
xenobiotics into more polar metabolites that are readily excreted. In humans and most mammals, P450 
family 1 comprises three well-studied monooxygenases, 1A1, 1A2, and 1B1. 
Cytochrome P450 1A1, a well-known aryl hydrocarbon hydroxylase, is implicated in the metabolic 
activation of environmental procarcinogens such as polycyclic aromatic hydrocarbons (PAHs)  
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and polyhalogenated aromatic hydrocarbons (PHAHs). Human P450 1A1 is mainly expressed in 
extrahepatic tissues such as lung, gastrointestinal tract, placenta, and skin, and is present only at low 
levels in the liver [1,2]. P450 1A1 is one of the most important enzymes involved in tumorigenesis 
initiated by environmental pollutants [3]. A number of epidemiological studies have shown that genetic 
variants of human CYP1A1 gene are significantly associated with the susceptibilities to lung and breast 
cancers [4–6]. Because of the significant role of P450 1A1 enzyme in human carcinogenesis, modulation 
of P450 1A1 activity has been considered as a potential target for cancer chemoprevention. 
P450 1A2 is one of the major cytochrome P450 enzymes in human liver (about 13%) responsible 
for the metabolism of a variety of arylamines and heterocyclic arylamines which include numerous 
therapeutic drugs such as phenacetin, lidocaine, tacrine, and theophylline [2,7]. P450 1A2 is  
notable for the capacity to N-oxidize arylamines, bioactivating arylamines such as 2-amino-3-methyl-
imidazo[4,5-f]quinoline (IQ) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) into 
potent mutagenic or carcinogenic compounds [8]. Procarcinogen activation by P450 1A2 has a 
significant effect on an individual’s susceptibility to cancer [8]. Inhibition of P450 1A2 also has 
implications in cancer prevention. 
Cytochrome P450 1B1 is found mainly in extrahepatic tissues as well as in a variety of human 
tumors. This has important implications for tumor development and progression. Metabolic activation 
of 17β-estradiol (E2) to 4-hydroxy-17β-estradiol by P450 1B1 has been postulated to be an important 
factor in mammary carcinogenesis [9–11]. Like P450 1A1, this enzyme also metabolically activates 
procarcinogens to carcinogenic forms, resulting in mutagenesis and tumorigenesis [9]. Thus, regulators 
of the expression and catalytic activity of P450 1B1 have been suggested to play an important role in 
cancer chemoprevention, especially at the early stage of tumorigenesis [12]. Recently, it has been 
observed that P450 1B1 could generate reactive oxygen species resulting in hypertension, which 
suggested that P450 1B1 inhibitors might be clinically useful in the treatment of hypertension and 
associated cardiovascular diseases [13]. 
To summarize, although P450 family 1 cytochromes are responsible for the metabolism of a wide 
variety of xenobiotics as well as endogenous compounds, the enzymatic reactions also produce 
reactive intermediates which can covalently bond to cellular macromolecules leading to toxicity, 
mutagenicity, and carcinogenicity. Hence, much emphasis has been on the inhibition of these enzymes 
to develop potential cancer preventative and therapeutic agents [2,3,9,14]. The potential anti-cancer 
strategies targeting P450 inhibition were postulated as: (i) preventing the conversion of environmental 
procarcinogens to active carcinogens; (ii) preventing the conversion of hormonal precursors to 
carcinogenic hormone derivatives; and (iii) preventing the metabolic inactivation of anti-cancer  
drugs [15]. Herein we will review multifarious inhibitors of cytochrome P450 family 1 enzymes, 1A1, 
1A2, and 1B1. 
2. Classified Inhibitors of P450s 1A1, 1A2, and 1B1 
Because of their high structural and functional similarity, cytochrome P450s 1A1, 1A2, and 1B1 are 
known to have overlapping substrates, inducers, and inhibitors. Therefore, the development of 
selective inhibitors towards any of these enzymes is a great challenge. To date, thousands of 
compounds (including natural products, pharmaceuticals, and synthetic compounds) have been 
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evaluated for their inhibitory activities toward P450 family 1 enzymes. In an early study, the inhibition 
effects of 12 compounds toward P450s 1A1 and 1A2 were investigated, including α-naphthoflavone, 
ellipticine, 7-ethoxyresorufin, 5-methoxypsoralen, 8-methoxypsoralen, 7-ethoxycoumarin, nifedipine, 
propranolol, caffeine, paraxanthine, theophylline, and theobromine [16]. The comparison between 
groups indicated that polycyclic aromatic hydrocarbons, flavones, and coumarins were highly potent 
P450 inhibitors with IC50 values in the micromolar level. This review mainly focuses on the highly 
potent inhibitor groups, which are more likely to become chemopreventive agents. 
2.1. Polycyclic Aromatic Hydrocarbons 
Since PAHs such as benzo[a]pyrene (B[a]P) are classical substrates of P450 family 1 enzymes, a 
number of PAHs were examined as inhibitors of the three enzymes through 7-ethoxyresorufin  
O-deethylation (EROD) assay by Shimada et al. The simplest PAHs, anthracene and phenanthrene 
(Figure 1), showed stronger inhibition toward P450 1A2 over the other two enzymes. On the other 
hand, the four-ring pyrene structure showed extremely strong inhibition of P450 1B1 with an IC50 of  
2 nM, but not much selectivity relative to P450 1A2 [17]. The most potent inhibitor of P450 1A2 was 
benz[a]anthracene (IC50 = 2 nM), exhibiting 8.9-fold and 7.0-fold more effective inhibition of this 
enzyme relative to P450s 1A1 and 1B1, respectively [17]. A follow-up study showed that the complex 
PAHs (Figure 1), such as chrysene, benzo[e]pyrene, 3-methylcholanthrene (3MC), fluoranthene (FA), 
and benzo[b]fluoranthene (B[b]FA), exhibited nanomolar level inhibition of P450 1B1-mediated 
EROD activity [18]. Mechanism investigation showed that all the studied non-substituted PAHs acted 
as competitive inhibitors [17,18]. 
Figure 1. Polycyclic aromatic hydrocarbons as P450 family 1 inhibitors. 
 
Polycyclic aromatic hydrocarbons appear to be strong inhibitors of P450s 1A1, 1A2, and 1B1. 
However, PAHs (such as benzo[a]pyrene, 3-methylcholanthrene, and 7,12-dimethylbenz[a]anthracene 
(DMBA)) have also been linked to tumor formation and cancer in humans. Thus, even though PAHs 
have already become useful tools to investigate the structure and function of P450 family 1 enzymes, it 
is not logical to design therapeutic agents using them. 
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2.2. Naphthoquinones and Anthraquinones 
Naphthoquinones and anthraquinones could be considered as oxygen-substituted naphthalenes and 
anthracenes, respectively. Various naphthoquinone derivatives, including 1,2-naphthoquinone and  
1,4-naphthoquinone, are known ingredients of Chinese traditional medicines. The inhibitory effects of 
six derivatives of 1,4-naphthoquinone (NQ) on rat cytochrome P450 1A1-dependent EROD activity 
were examined using yeast microsomes containing overexpressed rat P450 1A1. Of these NQs,  
5-hydroxy-2-methyl-NQ, 2-methyl-NQ, 2-hydroxy-NQ, and NQ showed competitive inhibition, 
whereas 5,8-dihydroxy-NQ and 5-hydroxy-NQ showed non-competitive inhibition [19]. The Ki values 
for these compounds are shown in Figure 2. The most potent compound is 5-hydroxy-NQ with a Ki 
value of 1.8 µM [19]. Anthraflavic acid (2,6-dihydroxyanthracene-9,10-dione, Figure 2), a naturally 
occurring plant phenol, inhibited aryl hydrocarbon hydroxylase (AHH) activity in microsomes 
prepared from control and 3-methylcholanthrene-pretreated SENCAR mice with a Ki value of 165 µM, 
and inhibited ethoxycoumarin O-deethylase and EROD activities [20]. 
































































Ki for 1A1 6.5 uM [19]
IC50 for 1A1 0.98 uM [21] 1A1 0.96 uM [21]
IC50 for 1A1 0.40 uM
1A2 0.53 uM [23] 1A1 2.09 uM
1A2 0.53 uM [23]
1A1 0.89 uM








1A1 1.8 uM [19] 1A1 4.1 uM [19]
Ki for 1A1 2.6 uM [19] 1A1 62 uM [19] 1A1 11 uM [19]
 
Fourteen commercially available naphthoquinone and anthraquinone derivatives were evaluated  
for their inhibition of N-hydroxylation activity of P450 1A1 toward Trp-P-2 (3-amino-1-methyl-5H-
pyrido[4,3-b]indole). Among these derivatives, alizarin (IC50 = 0.98 µM, Figure 2) and emodin  
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(IC50 = 0.96 µM, Figure 2) showed the most effective inhibition of P450 1A1 [21]. An in vitro assay 
also suggested that anthraquinones (especially quinizarin) affected the mutagenicity of IQ mainly 
through inhibiting the microsomal activating enzyme (P450 1A2) which metabolized IQ to active 
metabolite N-hydroxy-IQ [22]. 
Using emodin as a lead compound, 12 synthetic naphthoquinone and anthraquinone  
derivatives were investigated. Compounds 4-amino-1-chloro-3-methylanthraquinone, 4-amino-1-
hydroxy-anthraquinone, and 4-((3-methylbutan-2-yl)oxy)-3,4,4a,9a-tetrahydroanthracene-2,9,10(1H)-
trione were the most potent among the 12 derivatives, with IC50 values of 0.40, 2.09, and 0.89 µM  
for P450 1A1 and 0.53, 0.53, and 1.62 µM for P450 1A2, respectively. 4-Amino-1-chloro-3-methyl-
anthraquinone showed mechanism-based inhibition of both P450s 1A1 and 1A2 [23]. 
Since naphthoquinones and anthraquinones are natural products some of which have been used in 
Chinese traditional medicine for hundreds of years, their toxicity is much lower than that of PAHs. 
However, their efficacies for inhibiting P450 family 1 enzymes are also lower than those of PAHs and 
their structures need to be optimized to obtain highly potent and selective inhibitors of these enzymes. 
2.3. Stilbenoids 
trans-Stilbene, (E)-1,2-diphenylethene, is another main structural type of non-nitrogen P450 family 
1 inhibitors. The first studied stilbenoid as a P450 inhibitor was resveratrol (3,5,4'-trihydroxystilbene), 
which is a natural product found in red grapes. Resveratrol showed chemopreventive effects in both 
cardiovascular disease and cancer [24]. Resveratrol exhibited mild inhibition of human P450 1A1 in a 
dose-dependent manner, with an IC50 value of 23 µM for EROD and an IC50 value of 11 µM for 
methoxyresorufin O-demethylation (MROD). However, the inhibition of human P450 1A2 by 
resveratrol was over 50-fold weaker than that of P450 1A1 (IC50 1.2 mM for EROD and 580 µM for 
MROD) [24]. Mechanism investigation showed that resveratrol inhibited human P450 1A1 activity in 
a mixed-type inhibition (competitive-noncompetitive) with Ki values of 9 µM (for competitive 
inhibition) and 89 µM (for non-competitive inhibition). Resveratrol is also a noncompetitive inhibitor 
of human P450 1B1 (with Ki = 23 µM) [24] and a mechanism-based inactivator of cytochrome P450 
3A4 (KI and kinact values of 20 µM and 0.20 min
−1, respectively) [25]. On the other hand, resveratrol 
was shown to be an arylhydrocarbon receptor (AhR) antagonist, inhibiting the induction of P450  
1A1 [26]. Resveratrol inhibited TCDD-induced CYP1A1 expression in HepG2 cells (in vitro) through 
blocking the induction of DRE (dioxin-responsive element)-driven transcription by AhR [27]. In an 
animal model, resveratrol was able to abrogate B[a]P-induced P450 1A1 activity and subsequent 
formation of B[a]P-DNA adducts [28]. 
To find more effective inhibitors toward P450 1A1, a group of natural and synthetic 
hydroxylstilbenes (Figure 3) were investigated for their P450 inhibition activities by Chun et al. 
Monomethylation of the 4'-hydroxyl group (3,5,3'-trihydroxy-4'-methoxystilbene (rhapontigenin) and 
3,5-dihydroxy-4'-methoxystilbene) increased the inhibitory activities and kept the selectivity for  
P450 1A1, while multi-methylation (3,4'-dimethoxy-5-hydroxystilbene and 3,5,4'-trimethoxystilbene) 
improved the inhibitory potency toward both P450s 1A1 and 1A2, resulting in the loss of selectivity 
toward P450 1A1. The inhibitory activities toward P450 1B1 were also determined in this study [29]. 
Among these stilbenes, rhapontigenin extracted from Rheum undulatum was shown to be a 
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mechanism-based inactivator of P450 1A1 with an IC50 value of 0.4 μM [30]. Rhapontigenin showed 
400-fold selectivity toward P450 1A1 over P450 1A2 (IC50 = 160 μM) and 23-fold selectivity toward 
P450 1A1 over P450 1B1 (IC50 = 9 μM) [29]. 
2,4,3',5'-Tetramethoxystilbene (2,4,3',5'-TMS, Figure 3), a methoxy derivative of oxyresveratrol 
was found to be the most selective competitive inhibitor of P450 1B1, with an IC50 value of 6 nM in a 
group of 3,5-dimethystilbene derivatives [30,31]. 2,4,3',5'-TMS exhibited 50-fold selectivity for  
P450 1B1 over P450 1A1 (IC50 = 300 nM) and 500-fold selectivity for P450 1B1 over P450 1A2  
(IC50 = 3 μM) in EROD assay [30]. 2,4,3',5'-TMS strongly inhibited 4- and 2-hydroxylation of  
17β-estradiol by P450 1B1-expressing membranes or purified P450 1B1 [30]. 2,4,3',5'-TMS also 
showed suppression of TCDD (2,3,7,8-tetrachlorodibenzodioxin)-induced CYP1B1 expression in 
MCF-7 cells and HL-60 cells [32]. In the same study, 3,4,5,3',5'-pentamethoxystilbene (PMS) and 
3,5,3',5'-tetramethoxystilbene were found to be selective inhibitors toward P450 1A1 (Figure 3) [31]. 
PMS, a heavily-studied compound, produced a significant inhibition of EROD activities with IC50s of 
0.14, 934, and 3.2 μM for P450s 1A1, 1A2, and 1B1, respectively. Moreover, PMS significantly 
suppressed P450 1A1-mediated EROD activity and CYP1A1 gene expression induced by TCDD in 
HepG2 cells [33]. 
Figure 3. Stilbenoids as P450 1A1, 1A2, and 1B1 inhibitors. 
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2,4,2',6'-Tetramethoxystilbene is another potent and specific inhibitor of P450 1B1. 2,4,2',6'-TMS 
exhibited potent and selective inhibition of EROD activity of P450 1B1 with an IC50 value of 2 nM. 
2,4,2',6'-TMS exhibited 175-fold selectivity for P450 1B1 over 1A1 (IC50, 350 nM) and 85-fold 
selectivity for P450 1B1 over 1A2 (IC50, 170 nM). 2,4,2',6'-TMS significantly suppressed EROD 
activity and CYP1A1 and CYP1B1 induction by TCDD in human tumor cells such as HepG2 and  
MCF-10A [34]. 
Some stilbene derivatives with a methylthio substituent were shown to be selective and  
potent inhibitors of P450 family 1 [35]. Among this series of compounds studied, 2-methoxy-4'-
methylthiostilbene, 2,3-dimethoxy-4'-methylthiostilbene, and 2,3,4-trimethyoxy-4'-methylthiostilbene 
(Figure 3) were the most potent competitive inhibitors of P450 family 1 enzymes [12,35]. Especially, 
2,3,4-trimethoxy-4'-methylthiostilbene was the most selective inhibitor of P450s 1A1 and 1B1, 
displaying extremely low affinity toward P450 1A2 [12]. 
In summary, 2,4,3',5'-tetramethoxystilbene and 2,4,2',6'-tetramethoxystilbene appear to be potent 
and specific inhibitors of P450 1B1 [30,34]. Rhapontigenin and 2,3,4-trimethyoxy-4'-methyl-thiostilbene 
are the most selective inhibitors toward P450s 1A1 and 1B1 over P450 1A2 [29,34]. Meanwhile, 
3,5,4'-trimethoxystilbene exhibits comparable inhibitory activities toward all of the family 1 P450 
enzymes. Because of the excellent selectivity toward P450s 1A1 or/and 1B1 and the capability of 
inhibiting AhR-induced Phase I metabolizing enzyme expression, trans-stilbenes are considered  
to be promising potential chemopreventive agents for both environmental carcinogen-induced and  
(17β-estradiol) E2-related tumorigenesis. 
2.4. Flavonoids 
Flavonoids are widely present in fruits, nuts, vegetables, and medical herbs. These compounds have 
been described as health-promoting as well as disease-preventing dietary supplements [36]. The 
relative safety of flavonoids has allowed them to be used as therapeutic agents in traditional and 
modern medicine. Evidence indicates that certain flavonoids have high potency and selectivity for 
inhibition of P450 1A enzymes. This fact may have important implications for cancer prevention, as 
well as other pharmacological and toxicological effects [37]. 
By contrast with stilbene, the flavone core is a less potent inhibitor of P450 1A1 (IC50 = 0.14 µM) 
than P450 1A2 (IC50 = 0.066 µM). Hydroxyflavones were investigated as well, however they  
showed diverse selectivity toward P450 1A subfamily members. For example, 5-hydroxyflavone and 
5,7-dihydroxyflavone showed higher inhibition activity and selectivity toward P450 1A2 compared to 
P450 1A1 [37–39]. Whereas, 7-hydroxyflavone and 3,7-dihydroxyflavone exhibited 4–8 fold greater 
selectivity in their inhibition of P450 1A1 over 1A2 [37,38]. 3,5,7-Trihydroxyflavone (galangin, 
Figure 4) showed the highest potency toward P450 1A2. The inhibition of the MROD activity of P450 
1A2 by galangin was mixed-type, with a Ki value of 0.008 µM. Galangin showed a 5-fold selectivity in 
its inhibition of P450 1A2 over 1A1 [37,39]. 2'-, 3'-, and 4'-methyoxyflavones exhibited similar 
inhibitory activities toward P450s 1A1, 1A2, and 1B1 as the flavones core, while the introduction of a 
4'-methoxy- or 3',4'-dimethoxy group(s) into 5,7-dihydroxyflavone yielded active inhibitors of P450 
1B1 with IC50 values of 0.014 and 0.019 µM, respectively [39]. Six flavonyl propargyl ethers were 
also investigated for their inhibitory activities toward P450s 1A1 and 1A2. 3'-Propargyloxyfavone  
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(3'-PF) was the most potent inhibitor among these compounds. 3'-PF exhibited a 33-fold  
greater selectivity in its inhibition of P450 1A1 over P450 1A2, and it inhibited P450 1A1 in a 
mechanism-based manner [38]. 
An intergroup comparative study was carried out on the inhibition of P450 1B1 by flavonoid, 
stilbenoid, pyrene, naphthalene, phenanthrene, and biphenyl derivatives [40]. The results showed that 
3,5,7-trihydroxyflavone, 4'-methoxy-5,7-dihydroxyflavone, and 3',4'-dimethoxy-5,7-dihydroxyflavone 
were more active than flavone in interacting with P450 1B1. In a study of six naturally occurring 
flavonoids (acacetin, diosmetin, eriodictyol, hesperetin, homoeriodictyol, and naringenin), flavonone 
homoeriodictyol selectively inhibited P450 1B1 with a relatively high IC50 of 0.24 µM [41]. 
Figure 4. Structures of flavonoid inhibitors. 
 
Several naphthoflavone compounds acting as inhibitors of P450 family 1 enzymes have been 
investigated. α-Naphthoflavone exhibited a 10-fold higher inhibition of P450 1A2 than P450 1A1. 
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However, α-naphthoflavone did not show selectivity for inhibiting P450 1A2 compared with  
P450 1B1 [17,42]. On the contrary, β-naphthoflavone exhibited higher inhibition of P450 1A1 than 
1A2 [42]. To clarify the relationship between structural characteristic and selectivity, a series of 
pyranoflavone and 5-hydroxypyranoflavone derivatives were synthesized and examined for inhibition 
of P450s 1A1, 1A2, and 1B1. The results showed that α-naphthoflavone-like and 5-hydroxyflavone 
derivatives preferentially inhibited P450 1A2, while β-naphthoflavone-like flavone derivatives 
selectively inhibited P450 1A1. Interestingly, a highly selective P450 1B1 inhibitor, 5-hydroxy-4'-
propargyloxyflavone (5H4'FPE), was identified [42]. A study of four naphthoflavone propargyl ethers 
showed that 4'-propargyloxy-β-naphthoflavone (βNF4'PE, Figure 4) exhibited high inhibitory activity 
and selectivity toward P450 1A1 [39]. In comparison to stilbenes, flavonoids possess more affinity 
toward P450 1A2 compared to P450 1A1. Thus modifying flavone derivatives seems to be a logical 
approach to the design of selective P450 1A2 inhibitors as well as to study this enzyme’s active  
site cavity. 
As well-documented P450 inhibitors, the effects of flavonoids on AhR function and P450 family 1 
enzyme expression were also investigated in many studies [36]. Ciolino et al. reported that galangin 
(3,5,7-trihydroxyflavone) caused an increase in the amount of CYP1A1 mRNA, but inhibited the 
induction of CYP1A1 mRNA by DMBA or by TCDD in MCF-7 human breast cancer cells. Galangin 
also inhibited the DMBA- or TCDD-induced transcription of a reporter vector containing the CYP1A1 
promoter [43]. Quercetin and kaempferol are two of most abundant dietary flavonoids. Quercetin 
caused a time- and concentration-dependent increase in the level of CYP1A1 mRNA and P450 1A1 
enzyme activity in MCF-7 cells. However, kaempferol inhibited the TCDD-induced CYP1A1 
transcription instead of affecting normal CYP1A1 expression [44]. Baicalein (5,6,7-trihydroxyflavone, 
isolated from the plant Scutellariae baicalensis) reduce the CYP1A1/1B1 mRNA expression induced 
by DMBA, and the mRNA abundance for CYP1A1 appeared to be more responsive than that of 
CYP1B1 [45]. A flavone derivative, aminoflavone (Figure 4), also caused induction of CYP1A1 and 
CYP1B1 transcription through the AhR pathway [46]. Because of the two-way action of flavonoids on 
P450 enzyme inhibition and CYP gene expression, the true effects of a certain flavonoid in cell or  
in vivo are complex and need further investigation. 
2.5. Coumarins 
The most investigated coumarins, furocoumarin derivatives, were isolated from grapefruit juice and 
showed the capacity to inhibit the activity of certain human cytochrome P450 enzymes including P450 
family 1 enzymes [47]. Among these compounds, paradisin A, 6',7'-dihydroxybergamottin (DHB), and 
bergamottin (Figure 5) showed considerable inhibition of P450 1B1-mediated EROD activity with IC50 
values of 3.56 µM, 8.89 µM and 7.17 µM, respectively [47]. It has been reported that furocoumarins, 
angelicin, bergamottin, isopimpinellin, and 8-methoxypsoralen (8-MOP), effectively inhibited  
the catalytic activity of P450 1A1, but induced CYP1A1 gene expression via the AhR or non-AhR 
pathway [48]. As a recent study described, bergamottin and DHB inhibited alkoxyresorufin  
O-dealkylase activity of P450s 1A1 and 1A2 as well as the mutagenic effect of 3-MC and B[a]P in the 
Ames Test [49]. Cai et al. reported that several naturally occurring coumarins found in the human diet, 
including coriandrin, bergamottin, isoimperatorin, and ostruthin (Figure 5), were effective inhibitors of 
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hepatic EROD activity in vitro in hepatic tissues from SENCAR mice. Notably, bergamottin  
(IC50 = 0.12 µM) and coriandrin (IC50 = 0.85 µM) were approximately as potent as α-naphthoflavone 
(IC50 = 0.25 µM) [50]. Coriandrin was found to selectively inhibit P450 1A1-mediated EROD activity 
and to be a mechanism-based inactivator of this enzyme in vitro [51]. Contrary to flavonoids, 
coumarins are more efficient inhibitors of P450s 1A1 and 1B1 compared to P450 1A2. 
The effect of furocoumarins on P450 expression was compared to flavones. Bergamottin and 
coriandrin were found to inhibit metabolism of B[a]P and DNA adduct formation in cultured mouse 
epidermal keratinocytes [52]. Bergamottin inhibited DMBA metabolism and blocked DNA adduct 
formation in Hepa-1 cells, but had little effect in 10T1/2 cells. In contrast, α-naphthoflavone 
completely blocked DMBA metabolism and DNA adduct formation in 10T1/2 cells, but had little 
effect in Hepa-1 cells [53]. However, imperatorin and isopimpinellin (Figure 5) inhibited DMBA 
bioactivation in both cell lines [53]. 
Figure 5. Coumarin derivatives as P450 family 1 inhibitors (MLM, mice liver microsome). 
 
The investigated synthetic coumarins included 6-substituted 3,4-benzocoumarins [54] and  
7-ethynylcoumarins [55]. A group of ethynyl coumarin derivatives was found to effectively inhibit 
P450 1A enzymes. Specifically, 7-ethynyl-4-trifluomethylcoumarin and 7-ethynyl-4-methylcoumarin 
exhibited higher inhibition of P450 1A2 over 1A1, while 7-ethynyl-3-phenylcoumarin showed higher 
potency of inhibition for P450 1A1 over 1A2 [55]. 
2.6. Alkaloids 
Alkaloids are a large group of naturally occurring N-containing compounds. Since some of these 
compounds possess planar structural characteristics, they have the potential to be P450 inhibitors [16]. 
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Ellipticine, a pyridocarbazole, was the first identified alkaloid inhibitor of P450 family 1 enzymes. It 
was isolated from Ochrosia elliptica Labill, well-known as an antineoplastic agent [56]. Although 
ellipticine showed a strong inhibition of EROD activity in rat liver microsomes (IC50 = 0.11 µM), its 
inhibitory potential was non-specific and P450s from subfamilies 2B, 2D, and 3A were also inhibited 
by this compound [57]. 
A caffeine analog, furafylline, was the first selective P450 1A2 inhibitor identified. The first 
indication that it might inhibit P450 1A2 in vivo was that furafylline dramatically increased the  
half-life (7- to 10-fold) of caffeine in healthy volunteers [58]. Furafylline is a potent inhibitor of P450 
1A2 phenacetin O-deethylase activity (IC50 = 0.07 µM) in human liver microsomes. However, P450s 
1A1, 2A6, 2C8, 2D6, and 3A3/4 were not inhibited by furafylline (IC50 > 500 µM) [59]. In another 
study, furafylline was found to be a mechanism-based inhibitor of P450 1A2 [60]. The inactivation of 
P450 1A2 by this compound was characterized by a Ki of 23 µM and a kinact of 0.87 min
−1. 
The indole alkaloid melatonin (N-acetyl-5-methoxytryptamine) is an endogen, which is a secretory 
product of the pineal gland [60]. Melatonin inhibited P450 family 1 enzymes, with apparent Ki values 
of 59 (1A1), 12 (1A2), and 14 µM (1B1). Treatment of MCF-10A human mammary epithelial cells 
with 300 μM of melatonin did not affect basal or B[a]P-inducible CYP1A1 or CYP1B1 expression [61]. 
Luotonin A, a pyrroloquinolinequinoline alkaloid originally isolated from Peganum nigellastrum, is 
a natural inhibitor of DNA topoisomerase I. Luotonin A inhibited P450 1A2-catalyzed phenacetin  
O-deethylation with an IC50 of 6.3 μM in human liver microsomes, but did not inhibit it in a  
time-dependent manner. Luotonin A was found to decrease human recombinant cDNA-expressed 
P450 1A1- and 1A2-catalyzed phenacetin O-deethylase activities simultaneously, with IC50 values of 
4.05 and 7.35 μM, respectively (Figure 6) [62]. 
Of the alkaloids, quinazolinocarboline rutaecarpine (a COX-2 inhibitor) showed the most potent and 
selective inhibitory effects on P450-catalyzed MROD and EROD activities in untreated mouse liver 
microsomes. The IC50 ratio of MROD (IC50 = 0.08 µM) to EROD (IC50 = 0.51) was more than 6 [63].  
A series of synthetic rutaecarpines were evaluated for inhibition of P450s 1A1, 1A2, and 1B1. Among 
the derivatives, 10- and 11-methoxyrutaecarpine (Figure 6) were the most selective P450 1B1 
inhibitors. 1-Methoxyrutaecarpine and 1,2-dimethoxyrutaecarpine were the most selective P450 1A2 
inhibitors [64]. 
Berberine, palmatine, and jatrorrhizine are antimicrobial protoberberine alkaloids, present in several 
medicinal herbs, such as Coptis chinensis (Huang-Lian) and Hydrastis canadensis (goldenseal). These 
protoberberines inhibited P450 1A1- and 1B1-catalyzed EROD activities, whereas CYP1A2 activity 
was barely affected. Kinetic analysis revealed that berberine noncompetitively inhibited EROD 
activities of P450s 1A1 and 1B1, whereas palmatine and jatrorrhizine caused either competitive or 
mixed-type inhibition. Among protoberberines, berberine caused the most potent and selective 
inhibitory effect on P450 1B1 with the lowest Ki value of 44 nM [65]. In vivo assays showed that AhR 
was activated by high doses of berberine (10–50 µM) after 6 and 24 h of incubation as revealed by 
CYP1A1 mRNA expression (HepG2 cells) and AhR-dependent luciferase activity (H4IIE.luc cells). 
Whereas, berberine was a potent inhibitor (IC50 = 2.5 µM) of P450 1A1 catalytic activity (EROD) in 
HepG2 cell culture and in recombinant P450 1A1 protein [66]. 
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Figure 6. Structures of alkaloids as P450 family 1 inhibitors (RLM, rat liver microsome; 
HLM, human liver microsome; MLM, mouse liver microsome). 
 
2.7. Other Natural Products 
Ueng et al. isolated and identified a group of P450 inhibitors from danshen (the dried root of  
Salvia miltiorrhiza), which is used in the treatment of angina pectoris, hyperlipidemia, and acute 
ischemic stroke. Among the seven components of danshen extract, tanshinone I, tanshinone IIA, and 
cryptotanshinone (Figure 7) were shown to be potent competitive inhibitors of P450 1A2 (IC50 = 0.75, 
1.3, and 0.75 µM, respectively) [67]. In Escherichia coli membranes expressing bicistronic human 
P450 1A enzymes, tanshinone IIA inhibited EROD activity of P450 1A1 with an IC50 48 times higher 
than that for P450 1A2 [68]. In vitro assays showed that tanshinones caused a significant time- and 
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concentration-dependent increase in the amount of CYP1A1 and CYP1A2 expression in HepG2 cells 
through a transcriptional activation mechanism [69]. Oral treatment of tanshinone IIA caused a  
dose-dependent increase of liver microsomal MROD activity in the arylhydrocarbon (Ah)-responsive 
C57BL/6J (B6) mice but not in (Ah)-nonresponsive DBA/2J (D2) mice. These results demonstrated 
that induction of P450 1A2 by tanshinone IIA depended on the Ah-responsiveness and occurred at  
pre-translational level [70]. 
Figure 7. Other naturally occurring products as P450 family 1 inhibitors.  
 
The compounds silybin and dehydrosylibin purified from the extract of the fruit of  
Silybum marianum showed considerable inhibition of human recombinant protein P450 1A1, with  
IC50 values of 22.9 µM and 0.43 µM, respectively. Silybin and dehydrosylibin inhibited basal and 
dioxin-inducible P450 1A1 catalytic activity in human keratinocytes (HaCaT) and human hepatoma 
cells (HepG2). The inhibitory effects of tested compounds were more pronounced in HaCaT cells than 
in HepG2 cells, and dehydrosilybin was a much stronger inhibitor than silybin [71]. 
Inhibitory effects of cannabidiol (CBD) and cannabinol (CBN), the two major constituents in 
marijuana, on catalytic activities of human cytochrome P450 family 1 enzymes were investigated. 
These cannabinoids inhibited EROD activity of recombinant P450s 1A1, 1A2, and 1B1 in a 
competitive manner. CBD most potently inhibited P450 1A1; the apparent Ki value (0.16 µM) was at 
least one-seventeenth of the values for the other P450 1 enzymes. On the other hand, CBN decreased 
the activity of P450s 1A2 and 1B1 (Ki = 0.079 and 0.15 µM, respectively) more effectively than P450 
1A1 (Ki = 0.54 µM) [72]. ε-Viniferin, a dimer of resveratrol, has also been studies and showed higher 
inhibitory activities toward P450s 1A1 and 1A2 than resveratrol [73]. 
2.8. Drugs 
Because of potential drug-drug interactions, the effects of drugs on P450 enzymes are of great 
importance in pre-clinical pharmacological studies as well as clinical trials. Since P450 1A2 is one of 
the major drug metabolizing enzymes, it has been the most investigated enzyme for the inhibitory 
effect of drugs. 
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Pifithrin α (PFTα, Figure 8), a p53 inhibitor, decreased P450s 1A1, 1A2 and 1B1 catalytic activities 
in a concentration-dependent manner. PFTα showed a selective inhibitory effect on P450 1B1 activity  
(IC50 = 0.021 µM), compared with the activities of P450s 1A1 (IC50 = 1.53 µM) and 1A2  
(IC50 = 0.77 µM) [74]. The contraceptive agent 17α-ethinyl estradiol (EE, Figure 8) appeared to cause 
selective inhibition of P450 1A1 (IC50 = 2.7 µM) over P450 1A2 (IC50 = 14 µM) [75]. The amiloride  
(a diuretic drug) derivative EIPA (5-(N-ethyl-N-isopropyl)amiloride, Figure 8) was found to cause a 
potent and dose-dependent inhibition of P450 1-related EROD activity in both liver cells and 
microsomes [76]. The antidepressant fluvoxamine (Figure 8) was a potent inhibitor of P450 1A2-mediated 
EROD activity (IC50 = 0.3 μM) in human liver microsomes, but caused weak inhibition of P450  
1A1-mediated EROD activity in human placental microsomes [77]. Anti-arrhythmic agent mexiletine 
(Figure 8) preferentially inhibited P450 1A enzymes in hepatic microsomes. The P450 1A2-mediated 
MROD activity was inhibited by mexiletine with a Ki of 6.7 μM [78]. The antifungal drug miconazole 
(Figure 8) appeared to be a competitive inhibitor against P450 1A2-mediated EROD and P450  
2D6-mediated debrisoquine 4-hydroxylation with IC50 values of 2.90 and 6.46 µM, respectively [79]. 
Figure 8. Drugs as P450 family 1 inhibitors. 
 
The chemoprotective agent oltipraz (OPZ, Figure 8) was a potent inhibitor of xenobiotic and 
procarcinogen oxidation activities in recombinant human P450 enzymes, with P450 1A2 being more 
affected than P450s 1A1, 1B1, 2E1, or 3A4 [80]. The success of OPZ as a chemoprotective agent 
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against the induction of hepatocarcinogenesis by aflatoxin B1 (AFB1) in rats depended principally on 
its ability to enhance detoxification by inducing phase II enzymes, especially glutathione transferases. 
However, OPZ also had an important inhibitory effect on the major P450 enzymes responsive for 
AFB1 metabolism, in primary cultures of human hepatocytes [81,82]. 
The phenothiazine neuroleptic perazine (Figure 8) showed potent inhibition of caffeine  
3-N-demethylation (Ki = 3.5 μM) and caffeine 1-N-demethylation (Ki = 5 μM) in both human liver 
microsomes and cDNA-expressed P450 1A2 (supersomes) [83]. Other investigated drugs (Figure 8) 
included rofecoxib [84,85], 1-aminobenzotriazole (ABT) [86,87], tacrine [88], isoniazid [89],  
lidocaine [90], and zileuton [91], etc. Since a large number of drugs are metabolized by P450 1A2, 
concerns have been raised about the potential interactions between these inhibitors and other P450 1A2 
substrate drugs. 
2.9. Other Synthetic Compounds 
DMPVT (2-[2-(3,5-dimethoxyphenyl)vinyl]thiophene), an analog of stilbene, significantly inhibited 
EROD activities with IC50 values of 61, 11, and 2 nM for P450s 1A1, 1A2, and 1B1, respectively. The 
DMBA-induced EROD activity in rat lung microsomes was also significantly inhibited by DMPVT in 
a dose-dependent manner. The mechanism of inhibition by DMPVT were non-competitive for the 
three enzymes [92]. 
The compound 343 (Figure 9) described by Sienkiewicz et al. caused a concentration-dependent 
decrease in the EROD activity of P450 1A1 (IC50 = 2 µM) and 1B1 (IC50 = 6.5 µM). There was only a 
modest inhibition of P450 1A2 activity [93]. Compound 343 also inhibited the upregulation of 
cytochrome P450 enzyme activities and CYP mRNA levels in cells treated with the AhR ligands, 
DMBA or TCDD [93]. 
Figure 9. Other synthetic inhibitors. 
 
Some chalcone, tetralone, and benzosuberone derivatives as well as 6-methyl-1,3,8-trichloro-
dibenzofuran (MCDF) exhibited inhibition of metabolic activation of carcinogen DMBA by P450 
family 1 enzymes and TCDD-induced CYP1A expression, respectively. [94,95]. 
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2.10. Mechanism-Based Inhibitors (MBIs) 
As hemoprotein monooxygenases, cytochrome P450s are responsible for the oxidation of a wide 
variety of xenobiotics and endogenous compounds. Once the oxidation reaction with a potential 
inhibitor produces reactive intermediate(s) that can covalently bond to the P450 active site, irreversible 
inactivation occurs [96,97]. This is the basis of mechanism-based inactivation, and these potential 
inhibitors are known as mechanism-based or suicide inhibitors. Because of the complete irreversible 
inactivation of the P450 enzyme, a mechanism-based inhibitor is much stronger than a competitive 
inhibitor with the same affinity for the enzyme. Thus, mechanism-based inhibitors are used in the 
design of specific enzyme-targeted drugs since they only affect the enzyme which can metabolize them 
into oxygenated active intermediate(s). Mechanism-based inhibitors are also of great interest to 
researchers because of their utility in elucidating the characteristics of enzyme active site cavities and 
enzymatic reaction mechanisms. 
Since mechanism-based irreversible inactivation (suicide inhibition) is characterized by a  
pseudo-first-order time-dependent and NADPH-dependent loss of the enzymatic activity, a large 
number of MBIs (Figure 10) have been identified according to these criteria. Some of these compounds 
have been reviewed in the earlier sections of this review. These MBIs include anthraquinone derivatives  
(4-amino-1-chloro-3-methylanthraquinone [23]), stilbenoids (rhapontigenin [29]), flavones  
(7-hydroxyflavone, 3-flavon propargyl ether [38]), coumarins (coriandrin [51]), alkaloids (furafylline [60]), 
synthetic drugs (1-aminobenzotriazole [86], tacrine [88], and oltipraz [80]). 
Many mechanism-based inhibitors were intentionally designed and synthesized employing a basic 
reactive unit, acetylene. The triple bond of these terminal acetylenes is oxidized by the P450 enzyme to 
form a reactive ketene intermediate by a 1,2-hydrogen shift. The ketene intermediate can then react 
with the heme nitrogen resulting in a time-dependent destruction of the heme [98–100] or covalently 
bond with a nucleophilic residue of the active site protein, thereby inactivating the enzyme [101,102]. 
The other important component of these compounds is a planar conjugated system, fitting the narrow 
active site cavity of P450 family 1 enzymes. A large group of ethynyl and 1-propynyl pyrenes, 
phenanthrenes, naphthalenes, and biphenyls were investigated in a series of studies on P450s 1A1, 
1A2, and 1B1 [17,18,103,104]. The results showed that inhibition mechanism varied for the different 
compounds and different enzymes. For example, 1EP (1-ethynylpyrene) is a mechanism-based 
inhibitor of P450 1A1, but a competitive inhibitor of P450s 1A2 and 1B1. While 1PP  
(1-(1-propynyl)pyrene) is a mechanism-based inhibitor of P450s 1A1 and 1A2, but a competitive 
inhibitor of P450 1B1 [18,103]. It was generally observed that replacing the terminal hydrogen of aryl 
acetylenes with a methyl group to convert ethynes into propynes enhanced the inhibition of  
P450 1A enzymes; in some instances, this modification converted a reversible inhibitor into a  
suicide inhibitor [103]. It was also observed that 2EPh (2-ethynylphenanthrene) and 2PPh  
(2-(1-propynyl)phenanthrene) more potently inhibited P450 1A1 than 1A2, whereas 9EPh  
(9-ethynylphenanthrene) and 9PPh (9-(1-propynyl)phenanthrene) selectively inhibited P450 1A2 over 
1A1 [17,103]. This suggests that the molecular shape of an inhibitor is critical for the inhibitor’s 
selectivity towards P450s 1A1 and 1A2, which will be further discussed in the following section. The 
studies on the 7-ethynylcoumarins and flavonyl propargyl ethers also provided mechanism-based 
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inhibitors of P450 1As, and certain structural characteristics of P450 1A1 and 1A2’s active site  
cavities [38,55]. 
Figure 10. Selective MBIs with acetylenic group. 
 
3. Structural Characteristics of P450s 1A1 and 1A2 Inhibitors 
The crystal structures of P450s 1A1, 1A2, and 1B1 have been elucidated in the recent years, and the 
apparent active site sizes ranked as 1A1 (524 Å3) > 1B1 (469 Å3) > 1A2 (441 Å3) [1,105,106]. These 
crystal structures are very useful for exploring active sites, enzyme-ligand binding, and related 
interactions. P450s 1A1 and 1A2 are most similar, sharing 72% amino acid sequence identity, while 
P450 1B1 has relatively low amino acid sequence identity with both P450s 1A1 (38%) and 1A2  
(37%) [1]. However, in terms of the 3D structures and the function of enzymes, P450 1A1 shows much 
more similarity to P450 1B1 than P450 1A2. In fact, P450 1A2 is largely responsible for the 
metabolism of aromatic amines, whereas P450s 1A1 and 1B1 metabolize polycyclic aromatic 
hydrocarbons and polyhalogenated aromatic hydrocarbons [2,107–109]. Furthermore, observations of 
crystal structures also show that similarity of active site cavities of P450s 1A1 and 1B1 is considerably 
more than that of P450s 1A1 and 1A2, indicating that selectively inhibiting P450s 1A1 and 1B1 is 
much more difficult than P450s 1A1 and 1A2 [1]. On the other hand, the P450 1A1 and 1A2 encoding 
genes (CYP1A1 and CYP1A2) are located head-to-head on human chromosome 15q24.1, suggesting a 
close correlation of CYP1A1 and CYP1A2 expression, while CYP1B1 gene is located on human 
chromosome 2p22.2. Thus, a certain gene expression regulator, such as an AhR ligand, that leads to 
the same effects on CYP1A1 and 1A2 transcription, probably leads to less or reverse effect on 
transcription of CYP1B1. Since some P450 inhibitors also regulate CYP gene expression, the effects of 
a single chemical entity on the level and activity of a P450 enzyme are complex and hard to predict. 
Herein, we attempted to explore the inhibitors’ selectivity toward P450s 1A1 and 1A2 by a  
meta-analysis. Due to the variations of the inhibitory activity data, originated from the use of different 
experimental methods in different research groups, the absolute IC50 values are not usable for this 
analysis. Thus, we defined the selectivity ratio (the ratio of IC50 values for P450s 1A1 and 1A2)  
in the same study as a parameter. The selective inhibitors were classified into two groups, 
IC50(1A1)/IC50(1A2) < 0.2 as selective 1A1 inhibitors (Group 1), and IC50(1A1)/IC50(1A2) > 5 as selective 
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1A2 inhibitors (Group 2), respectively. An alignment was carried out in each group, and the aligned 
images exhibited the structural characteristics of each group, which showed the features of the active 
site cavities of P450s 1A1 and 1A2. Twenty-seven compounds were selected as potential 1A1 inhibitor 
group, and 23 compounds were selected as potential 1A2 inhibitor group. Group 1 included berberine, 
palmatine, jatrorrhizine, rutaecarpine derivative 10, coriandrin, 7-ethynyl-3-phenylcoumarin, 17α-ethinyl 
estradiol, EIPA, 7-hydroxyflavone, isorhamnetin, 3'-propagyloxyflavone, β-naphtho- flavone, 
βNF4'PE, 6,5-pyranoflavone, 2PPh, CBD, resveratrol, rhapontigenin, 3,5-dihydroxy-4’-
methoxystilbene, oxyresveratrol, 3,4'-dimethoxy-5-hydroxystilbene, 2,4,3',5'-tetramethoxystilbene, 
3,4,5,3',5'-pentamethoxystilbene, 3,5,3',5'-tetramethoxystilbene, 2-methoxy-4'-methylthiostilbene,  
2,3-dimethoxy-4'-methylthiostilbene, and 2,3,4-trimethoxy-4'-methylthiostilbene. Group 2 included 
pyrene, 4PP, phenanthrene, 2EPh, 2PPh, benz[a]anthracene, furafylline, rutaecarpine, rutaecarpine 
derivative 5, rutaecarpine derivative 8, 7-ethynyl-4-methylcoumarin, 7-ethynyl-4-trifluomethyl-coumarin, 
melatonin, fluvoxamine, flavone, 5-hydroxyflavone, 3,5,7-trihydroxyflavone, tanshinone IIA,  
α-naphthoflavone, 7,8-pyranoflavone, 5-hydroxy-7,8-pyranoflavone, CBN, and DMPVT. 
The inhibitor structures were sketched in ChemDraw 13.0 (PerkinElmer, Inc., Waltham, MA, 
USA), and alignment was performed manually. The aligned images (Figure 11) obviously show that 
the skeleton of selective P450 1A1 inhibitors is a long strip shape with 12.3 Å in length and 4.6 Å in 
width, reflecting the narrow and long cavity of P450 1A1. While the skeleton of selective P450 1A2 
inhibitors is a triangle with side lengths 9.3 Å, 8.7 Å, and 7.2 Å, respectively, suggesting a narrow 
compact cavity for P450 1A2. These results demonstrate the structural characteristics of P450s 1A1 
and 1A2 inhibitors as well as the differences of P450s 1A1 and 1A2’s active site cavities, which could 
not be determined through the analysis of X-ray crystal structures of the two enzymes. 
Figure 11. Alignment images of group 1 and group 2 inhibitors. (A) Group 1 represents 
selective P450 1A1 inhibitors; (B) Group 2 represents selective P450 1A2 inhibitors. 
 
4. Conclusions 
In this paper, we have reviewed a large number of P450 family 1 enzyme inhibitors and determined 
the differences between P450s 1A1 and 1A2’s active site cavities by a meta-analysis, which will 
benefit the future inhibitor development. Since some P450 enzyme inhibitors are inducers of CYPs 
expression, the evaluation of selective P450 family 1 inhibitors should also consider their effects on 
the expression of CYP1s and other related genes. Thus, an integrated in solution, in cell, and in vivo 
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bioassay system should be established to comprehensively evaluate the effects of a P450 inhibitor on 
the enzymes, on the other drugs, and on the related diseases. In addition, because of the notable 
relationship between P450 1B1 and carcinogenesis, the development of highly selective P450 1B1 
inhibitors should be an important focus of research on the family 1 P450 enzymes. Due to the limited data 
about the selectivity toward P450 1B1, more comparative studies on P450 family 1 inhibitors are needed. 
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